Dulaglutide was approved by the US Food and Drug Administration (FDA) in 2014 and by the European Medicines Agency (EMA) in 2015 for subcutaneous administration once weekly to improve glycemic control in adults with DM2
Methodological limitations: Many previous studies have had small sample sizes or lack rigorous controls
Targeted nutrients like creatine, calcium, magnesium, and B12 support muscle, bone, and energy systems
[It has a] two-minute half life and then gets destroyed in the blood
Chronic inflammation around hair follicles can disrupt the normal hair growth cycle and lead to hair thinning
All participants in the tirzepatide treatment arms started the study at a dose of tirzepatide 2.5 mg once-weekly and then increased the dose in a step-wise approach at four-week intervals to their final randomized maintenance dose of 5 mg (via a 2.5 mg step), 10 mg (via steps at 2.5 mg, 5 mg and 7.5 mg) or 15 mg (via steps at 2.5 mg, 5 mg, 7.5 mg, 10 mg and 12.5 mg)